Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Kyowa Kirin Sees Steady Switch to Nesp Biosame, but Biosimilars Closing in at Full Steam
Kyowa Kirin has seen a steady switch from its flagship renal anemia treatment Nesp (darbepoetin alfa) to its so-called “biosame” version rolled out last summer, but biosimilar contenders are also faring strongly, President Masashi Miyamoto said at a virtual press…
To read the full story
Related Article
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





